Vinflunine

Vinflunine
Systematic (IUPAC) name
methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-[(4R,6R,8S)- 4-(1,1-difluoroethyl)- 8-(methoxycarbonyl)- 1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-b]indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate
Clinical data
AHFS/Drugs.com International Drug Names
Licence data EMA:Link
Pregnancy cat.  ?
Legal status ℞ Prescription only
Routes Intravenous
Identifiers
CAS number 162652-95-1 Y
ATC code L01CA05
PubChem CID 6918295
UNII 5BF646324K Y
Chemical data
Formula C45H54F2N4O8 
Mol. mass 816.92 g/mol
SMILES eMolecules & PubChem
 Y(what is this?)  (verify)

Vinflunine (INN, trade name Javlor) is a novel fluorinated Vinca alkaloid[1] undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University),[2] developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.

On November 23, 2007, Pierre Fabre and BMS announced that they are terminating their license agreement for the development of vinflunine.[3]

References

  1. ^ Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT (March 1998). "Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid". Biochem. Pharmacol. 55 (5): 635–48. doi:10.1016/S0006-2952(97)00505-4. PMID 9515574. http://linkinghub.elsevier.com/retrieve/pii/S0006-2952(97)00505-4. 
  2. ^ Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives Fahy, J.; Duflos, A.; Ribet, J.-P.; Jacquesy, J.-C.; Berrier, C.; Jouannetaud, M.-P.; Zunino, F. J. Am. Chem. Soc.; (Communication); 1997; 119(36); 8576-8577.
  3. ^ "Bristol -Myers Squibb press release - Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status". http://newsroom.bms.com/article_display.cfm?article_id=5223. Retrieved 2008-06-27.